RNA Clinical Trials Resources

  1. ESMO Congress 2025: Highlights From Berlin 11/24/2025

    Turn the insights from this year’s ESMO into action by partnering to accelerate innovation through smarter trial design, stronger biomarker planning, and truly global collaboration.

  2. How Are Therapeutic Radiopharmaceuticals Advancing Precision Oncology? 11/7/2025

    By directing radioactive isotopes straight to diseased tissue, these agents deliver potent, localized treatment while sparing healthy cells — a major leap forward for patients with metastatic or treatment-resistant cancers.

  3. Highlights From The 2025 International Hepatitis B Meeting 11/7/2025

    For biotech and pharmaceutical teams, the core message was clear: progress is accelerating, but success still depends on smart study design, fit-for-purpose endpoints, and operational execution.

  4. Therapeutic Radiopharmaceuticals: Clinical Research, CRO Enablers (2025) 11/7/2025

    Accelerate the future of precision oncology by driving innovation, optimizing clinical development, and expanding access to targeted therapies that transform patient outcomes.

  5. Using AI Tools In Hepatology Drug Development 10/27/2025

    Explore how AI can help overcome key challenges in hepatology trials — from site selection and patient matching to data integration and engagement — while ensuring diversity, privacy, and transparency.

  6. The Evolving RNA Landscape: Navigating Science, Strategy, And Global Markets 10/27/2025

    Learn how to streamline development, reduce costs, and accelerate the path to market for next-generation RNA therapies.

  7. Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO 9/2/2025

    In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional; it is essential to survival and success.

  8. Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows 9/2/2025

    Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.

  9. Why Bioanalysis Needs To Break Free From Manual Bottlenecks 9/2/2025

    Bioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.

  10. Navigating The Planning And Execution Of Multiregional Trials 8/27/2025

    Plan your first overseas study or expand an established pipeline; with the help of strategic insights to navigate complexities, maximize investment, and position new therapies for international success.